The Lotus Team is thrilled to have collaborated with both ERG and Concentric on this important trial. We are proud to have played a part in helping advance a potential new treatment for pain management. Congratulations Concentric!

Evolution Research Group would like to congratulate our colleagues at Concentric Analgesics on the recently published results of their compound, vocacapsaicin, in their recent bunionectomy trial. The published results highlight the compound’s efficacy in improving analgesia and reducing opioid use post-surgery, demonstrating benefits of a 50% reduction in opioid use in the first 96 hours vs placebo, with 37% overall pain reduction over the first week compared to placebo. The treatment effect lasted at least 2 weeks post-surgery without any local or systemic toxicity.

Lori Wright, CEO of Evolution Research Group, stated, “We are thrilled with these outstanding results and extend our heartfelt congratulations to all teams and clinical trial participants who made this advancement in pain medication management possible. We also thank our ERG site network who exclusively collaborated with Concentric Analgesics to achieve these remarkable results.” The findings suggest Vocacapsaicin’s potential to enhance patient outcomes in various surgical procedures would add a substantial achievement in pain management and public health.

Read more about the Safety and Efficacy of Vocacapsaicin for Management of Postsurgical Pain at https://pubs.asahq.org/anesthesiology/article/141/2/250/140092/Safety-and-Efficacy-of-Vocacapsaicin-for